Safety and Pharmacokinetics of the Combination Broadly Neutralizing Antibodies, 3BNC117-LS-J and 10-1074-LS-J, in Healthy American and African Adults

    Not Recruiting
Updated on 24 July 2021


Researchers at The Rockefeller University are testing the safety of two broadly neutralizing antibodies (bNAbs) that can bind to HIV and block the virus from entering blood cells; thereby protecting people from becoming infected with HIV.


In this study, we will test two experimental study products given either separately or together to see if they are safe, and to understand how long they last in the human blood. We hope to learn if there are side effects after receiving the study product(s), and how severe those side effects will be.

The two study products being tested are called 3BNC117-LS-J and 10-1074-LS-J. These two products which were discovered in patients with HIV are human antibodies against HIV that have been made in a laboratory. HIV is the virus that causes acquired immunodeficiency syndrome (AIDS). We are hoping that one day these antibodies can be used to prevent or treat HIV infection. 

Condition *Healthy Patient Studies, *Healthy Volunteers
Clinical Study IdentifierTX270576
Last Modified on24 July 2021

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note